Toggle light / dark theme

A massive dataset of 3,628 Type Ia Supernovae from the Zwicky Transient Facility is being released, offering new insights into cosmic expansion.

This unprecedented collection will refine how cosmologists measure distances and study dark energy. With high-precision data from cutting-edge telescopes, scientists aim to resolve discrepancies in the standard cosmological model and explore new physics.

A Game-Changing Dataset for Cosmology.

Molecular Dynamics (MD) simulation serves as a crucial technique across various disciplines including biology, chemistry, and material science1,2,3,4. MD simulations are typically based on interatomic potential functions that characterize the potential energy surface of the system, with atomic forces derived as the negative gradients of the potential energies. Subsequently, Newton’s laws of motion are applied to simulate the dynamic trajectories of the atoms. In ab initio MD simulations5, the energies and forces are accurately determined by solving the equations in quantum mechanics. However, the computational demands of ab initio MD limit its practicality in many scenarios. By learning from ab initio calculations, machine learning interatomic potentials (MLIPs) have been developed to achieve much more efficient MD simulations with ab initio-level accuracy6,7,8.

Despite their successes, the crucial challenge of implementing MLIPs is the distribution shift between training and test data. When using MLIPs for MD simulations, the data for inference are atomic structures that are continuously generated during simulations based on the predicted forces, and the training set should encompass a wide range of atomic structures to guarantee the accuracy of predictions. However, in fields such as phaseion9,10, catalysis11,12, and crystal growth13,14, the configurational space that needs to be explored is highly complex. This complexity makes it challenging to sample sufficient data for training and easy to make a potential that is not smooth enough to extrapolate to every relevant point. Consequently, a distribution shift between training and test datasets often occurs, which causes the degradation of test performance and leads to the emergence of unrealistic atomic structures, and finally the MD simulations collapse15.

In recent years, roboticists and computer scientists have developed a wide range of systems inspired by nature, particularly by humans and animals. By reproducing animal movements and behaviors, these robots could navigate real-world environments more effectively.

Researchers at Northeastern University in China recently developed a new H-shaped bionic robot that could replicate the movements that cheetahs make while running. This robot, introduced in a paper published in the Journal of Bionic Engineering, is based on piezoelectric materials, a class of materials that generate an electric charge when subjected to mechanical stress.

“The piezoelectric robot realizes linear motion, turning motion, and turning motion with different radii by the voltage differential driving method,” wrote Ying Li, Chaofeng Li and their colleagues in their paper. “A prototype with a weight of 38 g and dimensions of 150 × 80 × 31 mm3 was fabricated.”

The future is coming and much faster than we think. Let’s do an exercise of imagination, imagine, for a moment, being able to send information from one point to another without the need for cables, Wi-Fi or traditional signals, more or less like something telepathic, right? Well, that is precisely what scientists have recently achieved at the University of Oxford: teleporting data between two quantum computers. Although it may seem like science fiction or just news, the world.

Although, let’s lower the hype a little, the transmission distance of this experiment was less than two meters, but that doesn’t matter, what matters is having achieved this milestone of sharing information without the need for connections.

Imagine being able to see quantum objects with your own eyes — no microscopes needed. That’s exactly what researchers at TU Wien and ISTA have achieved with superconducting circuits, artificial atoms that are massive by quantum standards.

Unlike natural atoms, these structures can be engineered to have customizable properties, allowing scientists to control energy levels and interactions in ways never before possible. By coupling them, they’ve developed a method to store and retrieve light, laying the groundwork for revolutionary quantum technologies. These engineered systems also enable precise quantum pulses and act as a kind of quantum memory, offering an unprecedented level of control over light at the quantum level.

Gigantic Quantum Objects – Visible to the Naked Eye.

Among the most intriguing ideas is warp drive—a concept that challenges Einstein’s Theory of Relativity by suggesting faster-than-light travel might be possible by warping space and time.

In 1994, theoretical physicist Miguel Alcubierre introduced the idea of a space-time bubble that could contract distances ahead of a spacecraft while expanding them behind it. His model, known as the Alcubierre drive, suggested a loophole in relativity that could, in theory, allow faster-than-light travel. Yet, most scientists dismissed it as impossible due to extreme energy requirements.

Not everyone was ready to abandon the idea. Joseph Agnew, an undergraduate at the University of Alabama, set out to explore whether the theory held up mathematically. “If you fulfill all the energy requirements, they can’t prove that it doesn’t work,” he stated in a university press release.

Year 2024 😗


Modular tiles, 3D printed using sawdust leftover from CLT production, were joined together without additional fixings to create this pavilion showcased by Japanese firm Mitsubishi Jisho Design at Dubai Design Week.

The Warp is a teahouse pavilion developed by architects Kei Atsumi and Motoya Iizawa from Mitsubishi Jisho Design’s Tokyo headquarters, along with Singapore-based Vibha Krishna Kumar from Mitsubishi Jisho Design Asia.

The project showcases a production system developed by the architecture firm called Regenerative Wood, which uses a filament made from wood waste mixed with bioplastic to 3D print building components and furniture.

Year 2024 In The advent of advanced architectural buildings wanting to be more sustainable we could have 3D printed wood waste buildings that are as strong as steel and even fireproof even where the glass is made from transparent wood.


The new tower would be double the height of the current record-holder—that’s also in Milwaukee.

Basically fungi foods can cure nearly all diseases it just requires the right mushroom for the ailment.


Bioactive compounds and metabolites in mushrooms Mushrooms in ancient healing Edible mushrooms with therapeutic potency References Further reading

Fungi have gained significant attention in the field of phytomedicine as potential natural sources of bioactive compounds and secondary metabolites. Fungi that produce visible fruiting bodies are called macrofungi. Mushrooms are edible macrofungi mainly found in rainy and snow-melting seasons.

Mushrooms form macroscopic fruiting bodies that eventually produce and disperse spores. Mushroom spores contain all the essential components that are needed to produce a new fungus. Mushrooms can exist in nature in many forms, including leathery or woody, fleshy, or sub-fleshy forms.

Mushrooms are probably the most miraculous entities because each mushroom can aid in a different way to cure each illness in the human biology. Much like cannabis is actually a cure all for so many ailments in humans so in turn are mushrooms able to do the same.


Alzheimer’s disease (AD) stands as a formidable neurodegenerative ailment and a prominent contributor to dementia. The scarcity of available therapies for AD accentuates the exigency for innovative treatment modalities. Psilocybin, a psychoactive alkaloid intrinsic to hallucinogenic mushrooms, has garnered attention within the neuropsychiatric realm due to its established safety and efficacy in treating depression. Nonetheless, its potential as a therapeutic avenue for AD remains largely uncharted. This comprehensive review endeavors to encapsulate the pharmacological effects of psilocybin while elucidating the existing evidence concerning its potential mechanisms contributing to a positive impact on AD. Specifically, the active metabolite of psilocybin, psilocin, elicits its effects through the modulation of the 5-hydroxytryptamine 2A receptor (5-HT2A receptor). This modulation causes heightened neural plasticity, diminished inflammation, and improvements in cognitive functions such as creativity, cognitive flexibility, and emotional facial recognition. Noteworthy is psilocybin’s promising role in mitigating anxiety and depression symptoms in AD patients. Acknowledging the attendant adverse reactions, we proffer strategies aimed at tempering or mitigating its hallucinogenic effects. Moreover, we broach the ethical and legal dimensions inherent in psilocybin’s exploration for AD treatment. By traversing these avenues, We propose therapeutic potential of psilocybin in the nuanced management of Alzheimer’s disease.

Alzheimer’s disease (AD) is a progressive neurodegenerative disease that is the leading cause of dementia in the elderly population (Anonymous, 2021). It is characterized by the deposition of amyloid-beta (Aβ) plaques, tau neurofibrillary tangles, and neuroinflammation (Scheltens et al., 2021). The prevalence of dementia is expected to rise as the global population grows and ages, with projections estimating a significant increase in the number of cases (Anonymous, 2022b). In 2019, the total cost of healthcare, long-term care, and hospice services for individuals aged 65 years and older with dementia in the United States was estimated at $2.2billion, so AD imposes a substantial burden on individuals, families, society, and the economy (Anonymous, 2022a). The U.S. Food and Drug Administration (FDA) has approved seven drugs for the treatment of AD, including rivastigmine, donepezil, galantamine, memantine, memantine combined with donepezil, aducanumab and lecanemab.